ISPH's INS365 misses Phase III endpoint

Inspire (ISPH) said its INS365 ophthalmic eye drops to treat dry eye showed no difference between treatment and placebo groups on the primary efficacy endpoint in a 558-patient U.S. placebo-controlled Phase III trial. According to ISPH, the placebo effect in the Phase III study was higher than in the company's Phase II trial. ...